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Targeting mitochondria to overcome conventional and bortezomib/proteasome
inhibitor PS-341 resistance in multiple myeloma (MM) cells
Dharminder Chauhan, Guilan Li, Klaus Podar, Teru Hideshima, Constantine Mitsiades, Robert Schlossman, Nikhil Munshi,
Paul Richardson, Finbarr E. Cotter, and Kenneth C.Anderson
Bortezomib (PS-341), a selective inhibitor
of proteasomes, induces apoptosis in
multiple myeloma (MM) cells; however,
prolonged drug exposure may result in
cumulative toxicity and the development
of chemoresistance. Here we show that
combining PK-11195 (PK), an antagonist
to mitochondrial peripheral benzodiaz-
epine receptors (PBRs), with bortezomib
triggers synergistic anti-MM activity even
indoxorubicin-,melphalan-,thalidomide-,
dexamethasone-, and bortezomib-resis-
tant MM cells. No signiﬁcant cytotoxicity
was noted in normal lymphocytes. Low-
dose combined PK and bortezomib treat-
mentovercomesthegrowth,survival,and
drug resistance conferred by interleu-
kin-6 or insulin growth factor within the
MM bone marrow milieu. The mechanism
of PK  bortezomib–induced apoptosis
includes: loss of mitochondrial mem-
brane potential; superoxide generation;
release of mitochondrial proteins cyto-
chrome-c (cyto-c) and Smac; and activa-
tion of caspases-8/-9/-3. Furthermore,
PK  bortezomib activates c-Jun NH2
terminal kinase (JNK), which translocates
to mitochondria, thereby facilitating re-
lease of cyto-c and Smac from mitochon-
dria to cytosol. Blocking JNK, by either
dominant-negative mutant (DN-JNK) or
cotreatment with a speciﬁc JNK inhibitor
SP600125, abrogates both PK  bort-
ezomib–induced release of cyto-c/Smac
and induction of apoptosis. Together,
these preclinical studies suggest that
combining bortezomib with PK may en-
hance its clinical efﬁcacy, reduce atten-
dant toxicity, and overcome conventional
andbortezomibresistanceinpatientswith
relapsed refractory MM. (Blood. 2004;
104:2458-2466)
© 2004 by TheAmerican Society of Hematology
Introduction
Multiple myeloma (MM) remains fatal despite all available thera-
pies.1 Recent studies show that bortezomib/proteasome inhibitor
PS-341 induces apoptosis even in MM cells refractory to multiple
prior therapies including dexamethasone (Dex), melphalan, and
thalidomide.2,3 Based on our preclinical and clinical studies, the
FDA recently approved bortezomib for the treatment of relapsed
refractory MM.2,4 Although initial treatment with bortezomib
triggers apoptosis in MM cells, de novo PS-341 resistance ulti-
mately develops in some cases. Chemoresistance is associated with
defects in apoptotic signaling in response to drugs; overexpression
of antiapoptotic proteins, such as B-cell leukemia/lymphoma-2
protein (Bcl2) or inhibitors of apoptosis protein (IAPs),5 and
expression of multidrug resistance (MDR) and other resistance
genes6,7; and tumor cell binding to bone marrow (BM) extracellular
matrix proteins and BM stromal cells, as well as cytokines within
the BM microenvironment including interleukin-68 and insulin
growth factor-I (IGF-I).9-11 The mechanisms mediating bortezomib
resistance and strategies to overcome it are now being delineated.
Conversely, recent reports have linked mitochondria to cell
death; and alterations in expression and/or function of mitochon-
drial signaling proteins lead to chemoresistance and treatment
failure.12-14 For example, modulation of peripheral benzodiazepine
receptors (PBRs) alters the sensitivity of acute myeloid leukemic
cells to chemotherapy.15 PBRs are predominantly localized in
mitochondrial pores and function as a prosurvival/antiapoptotic
protein.16-18 Higher levels of PBR density have been noted in
rapidly proliferating breast cancer cells and correlate with tumor
malignancy and patient survival.16 PK-11195 (PK) blocks the
cytoprotective effects of Bcl2 against multiple chemotherapeutic
agents without any cytotoxic effects of its own.16 Inhibition of PBR
function by its antagonist PK-11195 (PK) sensitizesAML(MDR)
cells to daunorubicin and cytarabine, without associated toxicity to
normal myeloid cells.15 Importantly, PK facilitates apoptosis by
opening mitochondrial permeability transition pores (PTPCs).16,19
Moreover, PK also inhibits p-glycoprotein–mediated drug efﬂux
thereby enhancing daunomycin cytotoxicity.15 In the context of
MM, we and others have established a role of mitochondria during
both conventional and novel agent–triggered cell death.5,12-19
Whether targeting PBRs in MM cells can sensitize these cells to
bortezomibandovercomebortezomibresistanceremainsundeﬁned.
In the present study, we asked (1) whether inhibition of PBRs
using PK affects MM cell viability, and (2) whether combination of
minimally toxic doses of PK and bortezomib induces apoptosis in
MMcells,overcomesbortezomibresistance,andenhancesanti-MM
activity of bortezomib. We show that PK and bortezomib triggers
synergistic apoptosis, even in MM cells resistant to bortezomib, via
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pathways. Moreover, activation of c-Jun NH2 terminal kinase
(JNK) is an obligatory event during PK  bortezomib–induced
apoptosis in MM cells. These preclinical studies provide the
framework for clinical evaluation of PK in combination with less
toxic doses of bortezomib to inhibit MM cell growth and overcome
drug resistance.
Patients, materials, and methods
Cell culture and reagents
Dex-sensitive MM.1S and Dex-resistant MM.1R human MM cell lines20,21
were kindly provided by Dr Steven Rosen (Northwestern University,
Chicago, IL). Doxorubicin (Dox)–resistant (Dox-40) and melphalan-
resistant (LR-5) RPMI-8226 cells were kindly provided by Dr William
Dalton (Mofﬁt Cancer Center, Tampa, FL). The U266 MM cell line was
obtained from the American Type Culture Collection (Rockville, MD).
SUDHL-4 (DHL-4) lymphoma cells were kindly provided by Dr Margaret
Shipp, Dana Farber Cancer Institute, Boston. Human B-cell lymphoma cell
line RC-K8 was kindly provided by Dr Thomas Gilmore (Boston Univer-
sity, MA). All cell lines were grown in RPMI-1640 media supplemented
with 10% heat inactivated fetal bovine serum (FBS), 100 units/mL
penicillin, 100 g/mLstreptomycin, and 2 mM L-glutamine. Drug-resistant
cell lines were cultured with low doses of drugs to conﬁrm their lack of drug
sensitivity. MM cells were freshly isolated from patients relapsing after
multiple prior therapies including dexamethasone, melphalan, thalidomide,
or bortezomib. An informed consent was obtained from all patients in
accordance with the Helsinki protocol. Mononuclear cells were prepared
from MM patient BM samples by Ficoll-Hypaque density gradient centrifu-
gation. Tumor cells (97  2.0% CD138) were isolated by CD138
selection21 using CD138 (Syndecan-1) Micro Beads and theAuto magnetic-
activated cell separation (MACS), according to the manufacturer’s instruc-
tions (Miltenyi Biotec, Auburn, CA). Cells were treated with various
concentrations of PK-11195 (25, 50, 75, 100, 200 micromolar; Sigma
Chemical, St Louis, MO) and/or bortezomib (Millennium Pharmaceuticals,
Cambridge, MA).
Cell viability assays
Cell viability was assessed by 3-(4,5-dimethylthiozol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Chemicon International, Temecula,
CA) assay according to the manufacturer’s instructions (Roche Molecu-
lar Biochemical, Indianapolis, IN), with some modiﬁcations. Cells were
seeded in 96-well plates in RPMI-1640 medium containing 10% FBS.
PK or bortezomib was added 24 hours later and incubated for 24 hours.
Cells were also treated with PK  bortezomib in the presence or absence
of IL-6 (10 ng/mL)/IGF-I (50 ng/mL) and analyzed for cell viability, as
previously described.21,22
Quantiﬁcation of apoptosis
Cell Death Detection ELISAplus was used to quantitate cell death, as per the
manufacturer’s instructions (Roche Applied Sciences, Indianapolis, IN).
Apoptosis was also assessed by dual ﬂuorescence staining with DNA-
binding ﬂuorochrome Hoechst 33342 (HO) and propidium iodide (PI) to
quantitate the percentage of apoptotic (PIHO) cells using ﬂow cytometry
(The Vantage; Becton Dickinson, San Jose, CA), as previously described.23
Cell death was quantiﬁed byAnnexin V staining, as previously described.24
Mitochondrial membrane potential (m) and generation
of superoxide (O2) anions
Serum-starved MM.1S cells were treated with bortezomib (2 nM) alone, PK
(50 M) alone, or bortezomib  PK for 12 hours, with CMXRos added for
the last 20 minutes; stained with lipophilic cationic dye CMXRos (Mito-
tracker Red; Molecular Probes, Eugene, OR) in phosphate-buffered saline
(PBS) for 20 minutes at 37°C; and analyzed by ﬂow cytometry to assay for
alterations in m.25 Superoxide production was measured by staining
cells with membrane permeable dye dihydroethidium (HE), as previously
described.26 Superoxide anions oxidize HE to ﬂuorescent ethidium, permit-
ting analysis by ﬂow cytometry (The Vantage, FACScan; Becton Dickin-
son) using excitation at 480 nm and emission at 630 nm.
In vitro immune complex kinase assays
In vitro immune complex c-Jun kinase assays were performed as a measure
of JNK activity, as previously described.27
Preparation of cytosolic and mitochondrial extracts
from MM.1S MM cells
MM.1S cells were washed twice with PBS, and the pellet was suspended in
3volumesoficecoldbufferA(20mMHEPES[N-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid, pH 7.5], 1.5 mM MgCl2,1 0m MK C l ,1m M
EDTA [ethylenediaminetetraacetic acid], 1 mM EGTA [ethylene glycol
tetraacetic acid], 1 mM dithiothreitol [DTT], 0.1 mM phenylmethylsulfonyl
ﬂuoride [PMSF], and 10 g/mL leupeptin, aprotinin, and pepstatin A)
containing 250 mM sucrose. The cells were homogenized using a Dounce
homogenizer, and cytosolic or mitochondrial extracts were isolated as
previously described.27
Western blotting
Protein lysates were prepared and Western blot analysis was performed as
previously described.28 Brieﬂy, equal amounts of proteins were resolved by
10% or 12.5% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred onto nitrocellulose membranes. Filters were
blocked by incubation in 5% dry milk in PBST (0.05% Tween-20 in PBS)
and probed with anti–cytochrome-c (cyto-c); anti-Smac (kindly provided
byDrXiaodongWang,UniversityofTexasSouthwesternMedicalCenterat
Dallas); antitubulin (Sigma, St Louis, MO); and anti–caspases-8, -9, or -3
(Cell Signaling, Beverly, MA) antibodies (Abs). Blots were then developed
by enhanced chemiluminescence (ECL;Amersham,Arlington Heights, IL).
The immunoblots were scanned using an LKB produkter (Bromma,
Sweden) Ultrascan XL laser densitometer and analyzed with the Gelscan
software package (Bromma, Sweden). Signal intensity was determined in a
linear range and normalized to that for tubulin. Preparation of cell lysates
for poly adenosine diphosphate (ADP) (ribose) polymerase (PARP) immu-
noblot analysis was performed as described using C-2-10 anti-PARP
monoclonal antibody.29
Transient transfections
MM.1S cells were transiently transfected using the Cell line Nucleofector
kit V, according to the manufacturer’s instructions (Amaxa Biosystems,
Cologne, Germany), with vector alone or DN-JNK (kindly provided by Dr
Donald Kufe, Dana Farber Cancer Institute, Boston, MA), and cotrans-
fected with vector containing green ﬂuorescence protein (GFP) alone.
Following transfections, GFP-positive cells were selected by ﬂow cytom-
etry, treated with PK  bortezomib, and analyzed for cytotoxicity.
Results
PBR antagonist PK-11195 (PK) and bortezomib decreases
viability of MM cells
We ﬁrst determined whether PK affects the viability of Dex-
sensitive (MM.1S) or Dex-resistant (MM.1R) MM cells using an
MTT assay. As seen in Figure 1A, treatment of MM cells with PK
for 24 hours induces a signiﬁcant (P  .005) decrease in cell
viability in a dose-dependent manner in both cell lines. A 50%
decrease in viable cells was noted at 200 M. The median
inhibitory concentration (IC50) of bortezomib for both cells lines
w a s4t o6n M( P  .005; Figure 1B).
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Based on our viability data, we selected minimally toxic concentra-
tions of PK (50 M) and bortezomib (2 nM) to determine their
combined effect on MM cell viability. As seen in Figure 1C,
treatment of MM.1S or MM.1R MM cells with PK  bortezomib
for 24 hours induces synergistic growth inhibition. Median viabil-
ity after each treatment was as follows: bortezomib 
PK 	 12  1.2%; bortezomib alone 	 78  3.1%; and PK
alone 	 98% (P 	 .05, one-sided Wilcoxon rank-sum test). Simi-
larly, median viability of MM.1R cells was as follows: bort-
ezomib  PK 	 50  0.8%; bortezomib alone 	 95  2.4%; and
PK alone 	 115  6.1% (P 	 .04, one-sided Wilcoxon rank-sum
test). Isobologram analysis conﬁrmed a synergistic anti-MM activ-
ity of PK with bortezomib (combination index [CI]  1.0).
Moreover, maximal anti-MM activity was noted when PK and
bortezomib were given concomitantly than in other drug treatment
schedules (data not shown).
To conﬁrm whether decreases in MM cell viability in response
to PK  bortezomib are due to apoptosis, we performed both
Annexin V staining and poly ADP (ribose) polymerase (PARP)
cleavage assays. As seen in Figure 1D, treatment of MM.1S with
low doses of PK (50 M) and bortezomib (2 nM) triggered a
signiﬁcant(P  .003)increaseinAnnexinV–positivecells,whereas
neither agent alone induces apoptosis at these concentrations.
Examination of proteolytic cleavage of PARP, a hallmark of
apoptosis,30 demonstrated similar results (Figure 1E).
To exclude the possibility that synergistic anti-MM activity of
PK is speciﬁc to bortezomib, we performed experiments using
another proteasome inhibitor MG-132. MM.1S cells were treated
with PK (50 M), MG-132 (50 M), or PK  MG-132 for 24
hours, and then analyzed for viability by MTT assays. As seen in
Figure 1F, treatment of MM.1S cells with either PK or MG-132
alone triggered minimal decrease in viability, whereas PK 
MG-132 induced signiﬁcant cytotoxicity in these cells. Median
viability of cells after each treatment was as follows: PK 	 98%;
MG-132 	 99.1%; and PK  MG-132 	 13  1.2%; P  .005.
These ﬁndings suggest that PK has synergistic anti-MM activity
when combined with proteasome inhibitors other than bortezomib.
These data are consistent with prior studies demonstrating similar
effects of PK combined with other anticancer drugs against
leukemic cells.15
Combined PK and bortezomib treatment induces apoptosis
in drug-resistant MM cell lines and patient cells
Since PK  bortezomib triggered synergistic apoptosis in Dex-
resistant (MM.1R) MM cells, we asked whether similar effects
were also induced in other drug-resistant MM cells, including
doxorubicin- and melphalan-resistant RPMI-8226 MM cells. As
seen in Figure 2A, combined treatment with low doses of PK and
bortezomib induced marked decreases in viability of all these cell
types (synergy: CI  1.0). We next directly examined the effects of
PK  bortezomib on MM cells freshly isolated from patients
relapsing after multiple prior therapies including bortezomib
(Figure 2B, patient nos. 1-2), dexamethasone (Figure 2B, patient
nos. 3-4), and thalidomide (Figure 2B, patient no. 5). As seen in
Figure 2B, treatment of patient MM cells with PK (50 M) 
bortezomib (2 nM) for 24 hours signiﬁcantly (P 	 .05; n 	 2)
triggered apoptosis in all 5 patient MM cells, as measured by DNA
Figure 1. PK-11195 (PK) and bortezomib treatment triggers synergistic anti-MM activity in MM cell lines and patient MM cells. (A) Dex-sensitive (MM.1S, f) and
Dex-resistant (MM.1R, ) cells were treated with various concentrations of bortezomib (1-10 nM) for 24 hours and assessed for viability using MTT assays. Results are
means  SDs of 3 independent experiments (P  .005). (B) MM.1S (f) and MM.1R () cells were treated with various concentrations of PK (25-200 M) for 24 hours and
assessed for viability using MTT assays. Results are means  SDs of 3 independent experiments (P  .005). (C) MM.1S and MM.1R cells were treated with PK (50 M),
bortezomib (2 nM), or PK  bortezomib for 24 hours and assessed for viability using MTT assays (P 	 .05 for MM.1S cells and P 	 .04 for MM.1R cells, one-sided Wilcoxon
rank-rank sum test). Error bars indicate standard error. (D) MM.1S cells were treated with PK (50 M), bortezomib (2 nM), or PK  bortezomib for 24 hours and assessed for
apoptosis by Annexin V staining assays. Results are means  SDs of 3 independent experiments (P  .003). (E) MM.1S cells were treated with PK (50 M), bortezomib (2
nM), or PK  bortezomib for 24 hours and assessed for apoptosis by PARPcleavage assays.Total protein lysates were subjected to SDS-PAGE analysis. Immunoblot analysis
of the lysates was performed with anti-PARP Abs. FL indicates full length; CF, cleaved fragment. (F) MM.1S cells were treated with PK (50 M), MG-132 (50 M), or PK 
MG-132 for 24 hours and assessed for viability using MTT assays. Results are means  SDs of 3 independent experiments (P  .005).
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between PK and bortezomib overcomes conventional and bort-
ezomib drug resistance in MM cells.
PK  bortezomib decreases viability in bortezomib-resistant
lymphoma cells
Having shown that PK  bortezomib overcomes bortezomib
resistance in patient MM cells, we next examined whether it can
also trigger cell death in other bortezomib-resistant cell types. Our
recent study demonstrated SUDHL4 lymphoma cells are resistant
to bortezomib therapy,31 and we therefore next asked whether
PK  bortezomib affects the viability of these cells. SUDHL4
lymphoma cells were treated with PK (50 M), bortezomib (10
nM), or PK  bortezomib for 24 hours, and then analyzed for
viability by MTT assays. As seen in Figure 2Ci, PK  bortezomib
markedly (P  .005) decreased viability in these cells, whereas
either agent alone did not.These ﬁndings suggest that the treatment
with PK  bortezomib overcomes bortezomib resistance even in
other cell types besides MM. Furthermore, since our previous study
showed that bortezomib resistance in SUDHL4 is conferred by
high expression of heat shock protein 27 (Hsp-27),31-33 we next
determined whether Hsp-27 expression is altered in response to
either PK or PK  bortezomib in these cells. No signiﬁcant
changes in Hsp27 expression levels were noted in PK-treated cells;
however, treatment with PK  bortezomib markedly decreased
Hsp27 protein levels (data not shown).Together, these data indicate
that PK  bortezomib overcomes the major growth/survival and
chemoresistance mechanism mediated by Hsp-27 in SUDHL4
cells. Our data support the use of combining PK and bortezomib to
induce synergistic antitumor activity in bortezomib refractory
cancers besides MM.
Combined PK  bortezomib treatment overcomes
Bcl2-mediated protective effects
Our recent study showed that Bcl2 can modestly attenuate bort-
ezomib-triggered cell death in MM cells.3 We therefore examined
whether PK  bortezomib affects the viability of MM.1S MM cell
line stably transfected with the wild-type Bcl2 gene. As seen in
Figure 2Cii, PK (75 M)  bortezomib (5 nM) signiﬁcantly
(P  .05) decreased viability in Bcl2-overexpressing MM.1S cells
after 24 hours of treatment, whereas neither agent alone at these
concentrations reduced viability of these cells (Figure 2Cii).
Moreover, PK  bortezomib induces 23  1.5% less cell death in
Bcl2-transfected MM.1S cells than in vector alone–transfected
MM.1S cells (data not shown). These data suggest that Bcl2
confers residual protective effects despite combined treatment of
MM cells with PK  bortezomib.
Combined treatment with PK  bortezomib does not affect
viability of normal lymphocytes
We next examined whether PK  bortezomib affects the viability
of normal cells. Normal lymphocytes from 5 healthy donors were
treated with PK (50 M)  bortezomib (10 nM) for 24 hours, and
then analyzed for viability using MTT assays. In contrast to MM
cells, survival of normal lymphocytes from 5 healthy donors was
not signiﬁcantly altered (P 	 .21 from J-T trend test), even after
combined therapy with high-dose bortezomib (10 nM) and PK (50
M) (Figure 2D). Treatment of MM cells with high doses of PK
alone for 24 hours did not affect normal cell viability, whereas
bortezomib (20 nM) decreased cell viability by 20% to 30% at 24
hours (data not shown). These ﬁndings are consistent with another
study demonstrating the lack of cytotoxicity of PK at these doses
on normal lymphocyte viability.34 Furthermore, no signiﬁcant
apoptosis in normal lymphocytes was observed after treatment with
PK (50 M)  bortezomib (10 nM) for 24 hours (data not shown).
Taken together, these ﬁndings indicate that low-dose combined
treatment with PK  bortezomib does not signiﬁcantly affect
viability of normal cells.
Effect of PK  bortezomib treatment on the viability of patient
MM-derived bone marrow stromal cells (BMSCs)
MM cells are predominantly localized in the BM microenviron-
ment due to their adherence both to extracellular matrix proteins
and to BMSCs.35 This interaction between MM cells and BMSCs
Figure 2. Combined PK and bortezomib treatment trig-
gers synergistic anti-MM activity in human MM cell lines
and patient MM cells resistant to conventional drugs,
withoutaffectingtheviabilityofnormalPBMNCs.(A)MTT
assays were performed after incubation of RPMI-8226,
doxorubicin-resistant Dox-40, or melphalan-resistant (LR-5)
MM cell lines with indicated doses of PK bortezomib for 24
hours. Results are means  SDs from 3 independent
experiments (P  .0002 for all cells lines). (B) CD138 MM
patient cells (patient nos. 1-5) were treated with PK (50 M),
bortezomib (2 nM), or PK  bortezomib for 24 hours and
assessed for apoptosis using DNA fragmentation assays.
Values are means  SDs of triplicate samples (P 	 .05);
experiments were repeated 2 times with similar results.
(Ci) bortezomib-resistant SUDHL4 (DHL-4) lymphoma cells
were treated with indicated concentrations of PK, bort-
ezomib, or PK  bortezomib for 24 hours, and assessed for
viability by MTT assays. Results are means  SDs of 4
independent experiments (P  .005). (Cii) MM.1S cells were
stably transfected with Bcl2 construct; treated with indicated
concentrations of PK, bortezomib, or PK bortezomib for 24
hours; and assessed for viability using MTT assays. Results
are means SDs of 3 independent experiments (P  .005).
(D) Normal lymphocytes from 5 healthy donors were treated
with PK (50 M)  bortezomib (2 nM) for 24 hours, and
viability was assessed by an MTT assay. Each donor is
indicated by a distinct symbol. Results are the mean SD of
3 independent experiments (P 	 .21 from Jonchkeere-
Terpstra [J-T] trend test).
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growth and survival of MM cells, as well as protection against
drug-induced apoptosis.11 We therefore next examined whether PK
(100 M)  bortezomib (20 nM) affects viability of patient
MM-derived BMSCs. As seen in Figure 3A, treatment of BMSCs
(patient nos. 1-3) with PK  bortezomib for 48 hours did not
decrease their viability. DNA fragmentation assays conﬁrmed that
PK  bortezomib does not trigger cell death in BMSCs (data not
shown). Together, these ﬁndings suggest that PK  bortezomib
directly affects the viability of MM cells, but not BMSCs.
Treatment with PK  bortezomib overcomes the antiapoptotic
effects of human recombinant IL-6 (rIL-6) and recombinant
insulin growth factor-I (rIGF-I)
We next examined the effect of combined PK  bortezomib
treatment on the 2 major growth and survival cytokines present
within the BM microenvironment that protect against Dex-induced
apoptosis.36-39 MM.1S cells were treated with PK (50 M) 
bortezomib (2 nM) or Dex (0.5M), in the presence and absence of
IL-6 (10 ng/mL) or IGF (50 ng/mL). As seen in Figure 3B, the
median cell viability was 28  2.1% after treatment with PK 
bortezomib and 24  2.2% with PK  bortezomib  IL-6
(P 	 .23,Wilcoxon test), whereas median viability was 51  4.1%
after Dex therapy and 92  5.4% due to combined Dex  IL-6
treatment (P 	 .05, as determined by one-sided Wilcoxon rank-
sum test). Similar results were obtained using IGF-I: median
viability was 28  2.1% after therapy with PK  bortezomib and
24.7% after treatment with PK  bortezomib  IGF-I (P 	 .27)
(Figure 3B). Thus, neither IL-6 nor IGF-I block PK  bortezomib–
induced cytotoxicity in MM.1S cells. In contrast and as in our prior
studies,9,40 both IL-6 and IGF-I protect against Dex-induced
decreased MM.1S cell viability. Taken together, these data demon-
strate that PK  bortezomib overcomes the growth/survival effects
of cytokines present within the MM BM milieu.
Combined treatment with PK  bortezomib induces alterations
in mitochondrial membrane potential (m), generation of
superoxide (O2
), release of mitochondrial proteins
cytochrome-c and Smac, and activation of caspases
We next examined the molecular mechanisms whereby low-dose
combined treatment with PK and bortezomib triggers apoptosis in
MM cells. Stress-induced apoptosis correlates with loss of m
and generation of superoxide O2
; release of Cyto-c/Smac from
mitochondria to cytosol; and activation of downstream capases-9/-
3.27 In addition, mitochondria-independent apoptosis can occur via
a death-receptor–mediated caspase-8/3 pathway.12 Prior studies
have shown that high-dose PK induces apoptosis predominantly by
decreasing m; inhibiting Bcl2-mediated prosurvival/antiapop-
totic signaling; and activation of caspase-3.16,19,41,42 Moreover, we
and others have shown that bortezomib triggers both caspase-8–
and caspase-9–mediated apoptotic signaling, albeit at high concen-
trations (10-20 nM).3,27,34,43 Given the synergism observed between
PK and bortezomib in mediating anti-MM activity, we next
examined the apoptotic signaling cascades triggered by these
agents in MM cells.
Disruption of mitochondrial integrity is critical during stress-
induced cell death.12 We therefore ﬁrst determined whether treat-
ment with PK  bortezomib induces a loss in m. MM.1S cells
were treated with PK (50 M), bortezomib (2 nM), or PK 
bortezomib for 12 hours; stained with CMXRos; and analyzed by
ﬂow cytometry, as previously described.44 As seen in Figure 4A,
neither PK nor bortezomib treatment alone at these doses triggered
signiﬁcant decreases in m, whereas PK  bortezomib therapy
induced a marked decrease in m in MM.1S cells, evidenced by
an increase in number of CMXRos-negative cells (P  .005).
Since loss of m is associated with O2
 production,45 we next
determined whether PK  bortezomib also affects O2
 levels.
MM.1S cells were treated with PK (50 M), bortezomib (2 nM), or
PK  bortezomib for 12 hours; stained with dihydroethidium
(HE); and analyzed by ﬂow cytometry. In contrast to treatment with
either agent alone, combined treatment with PK  bortezomib
induced O2
 generation in these cells (Figure 4B). The increment in
superoxide levels correlated with the degree of PK  bortezomib–
induced apoptosis. O2
 generation was noted in response to higher
doses of each agent alone (data not shown).
Loss of m is associated with release of mitochondrial
proteins Cyto-c and Smac to the cytosol.46 We therefore next
examined whether Cyto-c or Smac release is similarly affected by
synergistic doses of PK  bortezomib. MM.1S cells were treated
with PK (50 M), bortezomib (2 nM), or PK  bortezomib;
cytosolic extracts were then prepared and subjected to immunoblot
analysis with anti–Cyto-c or anti-Smac Abs. As seen in Figure 4C
(upper and middle panels), treatment of MM.1S cells with PK 
bortezomib induces the release of both Cyto-c and Smac. In
contrast, neither agent alone at these concentrations induced
signiﬁcant release of cyto-c and Smac. Importantly, PK  bort-
ezomib–induced Cyto-c or Smac release is 2- to 3-fold higher than
that induced by higher concentrations of bortezomib (10 nM)
(data not shown). Reprobing the immunoblots with antitubulin
Abs conﬁrms equal protein loading (Figure 4C, lower panel).
These ﬁndings show that O2
 generation is associated with
cyto-c– or Smac-mediated apoptotic signaling triggered in MM
cells by PK  bortezomib.
Figure 3. PK  bortezomib does not affect the viability of
patient MM-derived bone marrow stroma cells (BMSCs) and
overcome the antiapoptotic effects of interleukin-6 (IL-6) or
insulin growth factor-1 (IGF-1). (A) Patient MM BMSCs (patient
nos. 1-3) were treated with indicated concentrations of PK  bort-
ezomib for 24 hours and analyzed for viability by MTT assays. Results
are the mean  SD of 3 independent experiments; P  .005.
(B) MM.1S cells were treated with indicated concentrations of PK 
bortezomib or Dex (0.5 M) in the presence or absence of either IL-6
(10 ng/mL) or IGF (50 ng/mL). At 24 hours, cells were harvested and
viability was analyzed by MTT assays. Results are means  SDs of 3
independent experiments.
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Cyto-c/Smacfrommitochondriatocytosol,whichactivatescaspase-
9.46,47 We next therefore determined whether PK  bortezomib–
induced apoptosis is associated with caspase-9 activation by a
colorimetric assay. MM.1S cells were treated with PK, bortezomib,
or PK  bortezomib for 24 hours, and cytosolic extracts were
assayed for protease activity using LEHD-pNA as substrate. As
seen in Figure 4D, treatment of MM.1S cells with PK 
bortezomib, but not with PK or bortezomib alone, activates
caspase-9, as determined by LEHD-pNA cleavage. Since prior
studies have shown that a high dose of bortezomib induces
extrinsic apoptotic signaling via caspase-8 activation,3,48 we further
examined whether a nontoxic dose of bortezomib (2 nM) in
combination with PK can also trigger caspase-8 activation.As seen
in Figure 5A (upper panel), PK  bortezomib, but not either agent
alone, triggered marked caspase-8 cleavage. Both caspase-9 (mito-
chondria-dependent/intrinsicpathway)andcaspase-8(mitochondria-
independent/extrinsic pathway) are known to activate a common
downstream effector procapsase-3,49 and our data further showed
that PK  bortezomib triggered caspase activation, as evidenced
by caspase-3 cleavage (Figure 5A, lower panel). These data
demonstrate that combined treatment with subtoxic concentrations
of PK and bortezomib triggers mitochondrial perturbations sufﬁ-
cient to initiate apoptotic signaling, and suggest that this strategy
may avoid dose-related toxic effects of therapy with bortezomib
alone at higher concentrations.
To determine whether caspase activation is required for PK 
bortezomib–triggered apoptosis, we treated MM.1S cells with
caspase-8 inhibitor (IETD-fmk), caspase-9 inhibitor (LEHD-fmk),
or pan-caspase inhibitor (z-VAD-fmk). As seen in Figure 5B,
pan-caspase inhibitor, but not either caspase-8 or caspase-9 inhibi-
tor, abrogates PK  bortezomib–induced apoptosis. We also
determined whether caspase-9 activation triggers caspase-8 activ-
ity. The results demonstrate that inhibition of caspase-9 using
LEHD-fmk does not affect caspase-8 activity triggered by com-
bined PS  PK treatment of MM.1S cells (data not shown). These
data suggest that PS  PK–induced caspase-8 activity is not
secondary to activation of caspase-9. We next determined whether
PK  bortezomib–induced apoptosis requires caspase-3 activity.
Inhibition of caspase-3 using DEVD-fmk markedly abrogates
PK  bortezomib–triggered apoptosis (data not shown), as ob-
served using pan-caspase inhibitor.Together, these ﬁndings suggest
that (1) activation of both caspase-8 and caspase-9 is required, and
neither alone is sufﬁcient for PK  bortezomib–induced MM cell
death, and (2) caspase-3 activation is the predominant mechanism
whereby PK  bortezomib triggers MM cell apoptosis.
Treatment with PK  bortezomib induces activation of
cytosolic c-Jun NH2-terminal kinase (JNK) and
its translocation to mitochondria
Having shown that PK  bortezomib induces mitochondria-
dependent apoptotic signaling, we next examined an upstream
activator of this pathway. JNK has been linked to apoptosis: 2
serine residues (Ser63 and Ser73) in the amino-terminal transactiva-
tion domain of c-Jun are substrates for JNK,50,51 and previous
studies have shown that stress stimuli (eg, irradiation, tumor
necrosis factor, sphingomyelinase, and ultraviolet [UV] light)
activate JNK.50-52 Our prior studies showed that bortezomib
induces JNK activation in MM cells, albeit at higher doses (8-10
nM).27,48 In the present study, we therefore examined whether
low-dose bortezomib (2 nM) in combination with PK (50 M)
trigger JNK activation. MM.1S cells were exposed to PK 
bortezomib for various time intervals, and JNK activity was
Figure 4. PK  bortezomib changes mitochondrial membrane potential (m),
generation of superoxide (O2
), release of mitochondrial proteins Cyto-c and
Smac, and activation of caspase-9. (A) MM.1S cells were treated with PK (50 M),
bortezomib (2 nM), or PK  bortezomib for 12 hours; incubated with CMXRos for the
last 20 minutes; and analyzed by ﬂow cytometry to assay for alterations in m.
Increase in the number of CMXRos-negative cells indicates loss in m. Results are
means  SDs of 3 independent experiments (P  .005). (B) MM.1S cells were
treated with PK (50 M), bortezomib (2 nM), or PK  bortezomib for 12 hours;
harvested; stained with membrane permeable dye dihydroethidium (HE) for the last
15 minutes; and analyzed by ﬂow cytometry. Results are means  SDs of 3
independent experiments (P  .005). Superoxide anions oxidize HE to ﬂuorescent
ethidium, permitting analysis by ﬂow cytometry. (C) MM.1S cells were treated with PK
(50 M), bortezomib (2 nM), or PK  bortezomib for 24 hours and harvested;
cytosolicproteinswereseparatedby12.5%SDS-PAGEandanalyzedbyimmunoblot-
ting with anti–cyto-c (top panel) or anti-Smac (middle panel) Abs. As a control for
equal loading of proteins, ﬁlters were also reprobed with antitubulin Ab (bottom
panel). Blots are representative of 3 independent experiments. IB indicates immuno-
blot. (D) MM.1S cells were treated with PK (50 M), bortezomib (2 nM), or PK 
bortezomib for 24 hours. Cytosolic extracts were assayed for protease activity using
LEHD-pNA as substrate as per the manufacturer’s instructions (colorimetric assay
kit; Biovision, Palo Alto, CA). Results are representative of 3 independent experi-
ments (mean  SD, P  .005).
Figure 5. PK  bortezomib–induced apoptosis is associated with activation of
caspase-8 and caspase-3. (A) MM.1S cells were treated with PK (50 M),
bortezomib (2 nM), or PK  bortezomib for 24 hours; cytosolic proteins were
separated by 12.5% SDS-PAGE and analyzed by immunoblotting with anti–
caspase-8 (top panel) and anti–caspase-3 (bottom panel)Abs. Blots are representa-
tive of 3 independent experiments. FL indicates full length; CF, cleaved fragment. (B)
PK  bortezomib–induced apoptosis is mediated by both caspase-8, caspase-9 


caspase-3 pathway. MM.1S cells were treated with PK  bortezomib alone or in the
presence of caspase-8 inhibitor, caspase-9 inhibitor, or pan–caspase-3 inhibitor for
24 hours; harvested; and assessed for viability using MTT assays. Results are
means  SDs of 3 independent experiments (P  .005).
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as a substrate. As seen in Figure 6A (upper panel), analysis of
anti-JNKimmunoprecipitatesdemonstratedsigniﬁcant(7-to8-fold)
increases in GST-Jun phosphorylation, indicating activation of
JNK. Moreover, cotreatment of MM.1S cells with SP600125, a
speciﬁc inhibitor of JNK,53 blocks PK  bortezomib–induced JNK
activity (Figure 6A, upper panel). Importantly, synergistic doses of
PK and bortezomib induce greater JNK activation compared with
the high-dose bortezomib (10 nM) alone (Figure 6A, upper panel).
Activation of JNK in response to PK  bortezomib is not associated
with changes in JNK protein levels (Figure 6A, lower panel). Our
ﬁndings are in concert with studies ofVerheij et al, which demonstrate a
role of JNK in ceramide- andTNF-–induced apoptosis.52
Genotoxic stress triggers translocation of JNK from the cytosol
to mitochondria,13 thereby facilitating the release of mitochondrial
apoptogenic proteins to cytosol. To determine whether PK 
bortezomib–activated JNK translocates to mitochondria, we as-
sayed for JNK protein levels in cytosolic and mitochondrial
fractions from untreated versus PK  bortezomib–treated MM.1S
cells. As seen in Figure 6B (upper panel), treatment with PK 
bortezomib signiﬁcantly increases JNK protein level in the mito-
chondrial fraction (3- to 4-fold, measured by densitometric analysis
of immunoblots). Blots were reprobed with mitochondrial-speciﬁc
Hsp60 protein to conﬁrm purity of these fractions (Figure 6B,
lower panel). Together, these data demonstrate that PK  bortezo-
mib–induced apoptosis is associated with JNK activation and its
translocation to mitochondria.
Blocking JNK abrogates PK  bortezomib–induced
Cyto-c/Smac release and apoptosis
Given that activated JNK translocates to mitochondria and facili-
tates Cyto-c/Smac release in response to PK  bortezomib, we
next examined whether blocking JNK inhibits PK  bortezomib–
induced Cyto-c/Smac release and cell death. MM.1S cells were
treated with low-dose combination of PK (50 M)  bortezomib
(2 nM), in the presence or absence of JNK inhibitor SP600125 (10
M); cytosolic extracts were prepared and subjected to immuno-
blot analyses with anti–Cyto-c or anti-SmacAbs.As seen in Figure
7A (upper and middle panel), PK  bortezomib induces the release
of Cyto-c and Smac. Importantly, cotreatment with SP600125
signiﬁcantly inhibits release of both Cyto-c and Smac (Figure 7A,
upper and middle panel). Reprobing the immunoblots with antitu-
bulin conﬁrmed equal protein loading (Figure 7A, lower panel).
TheseﬁndingsdemonstratethatPKbortezomib–inducedapopto-
sis is mitochondria-mediated (intrinsic) signaling, since it requires
JNK activation to allow for its translocation and subsequent release
of Cyto-c/Smac.
We next directly examined the functional signiﬁcance of PK 
bortezomib–induced JNK activation. MM.1S cells were transiently
transfected with either DN-JNK or empty vector, and then treated
with low doses of PK (50 M) and bortezomib (2 nM); survival
was analyzed using MTT assay. As seen in Figure 7B, MM.1S
DN-JNK transfectants survived signiﬁcantly longer after treatment
with PK  bortezomib than cells transfected with vector alone:
median cell viability was 76% (24 hours), 56% (48 hours), and
45% (72 hours) after PK  bortezomib treatment of DN-JNK
transfected cells versus 32% (24 hours), 20% (48 hours), and 8%
(72 hours) after PK  bortezomib treatment of empty vector
transfected cells (P 	 .05, as determined by one-sided Wilcoxon
rank-sum test).
Discussion
Our study shows the following: (1) the combination of low doses of
PK and bortezomib triggers synergistic antitumor activity in MM
cells resistant to conventional and bortezomib therapy; (2) PK 
bortezomib does not affect the viability of normal cells; (3)
exogenous hIL-6 or hIGF-1 do not protect against PK  bortezo-
mib–induced apoptosis; (4) PK  bortezomib–induced apoptosis is
associatedwithcaspaseactivationandoccursviabothmitochondria-
dependent (loss of m, increase in O2
 production, release of
Figure 6. PK and bortezomib treatment triggers activation of c-Jun NH3-
terminal kinase (JNK) and translocation of JNK from cytosol to mitochondria in
MM.1S MM cells. (A) Cells were treated with PK (50 M), bortezomib (2 nM), PK 
bortezomib, PK  bortezomib  JNK inhibitor SP600125 (SP), or bortezomib (10 nM)
alone for 24 hours. Protein lysates were immunoprecipitated with anti-JNK Ab.
Immune complex kinase assays were performed by addition of 5 g GST-Jun
(2-100), (32P) adenosine triphosphate (ATP), and incubation for 15 minutes at 30°C.
The phosphorylated proteins were resolved by 10% SDS-PAGE and analyzed by
autoradiography (top panel). Anti-JNK immunoprecipitates were also immunoblotted
with anti-JNK Ab (bottom panel). Blots are representative of 3 independent experi-
ments with similar results. (B) MM.1S cells were treated with indicated concentrations
of PK  bortezomib for 24 hours. Cytosolic (Cyto) and mitochondrial (Mito) fractions
were isolated and subjected to immunoblotting with anti-JNK (upper panel) or
anti-Hsp60 (lower panel)Abs. Blots are representative of 2 independent experiments
with similar results.
Figure 7. JNK is involved during PK  bortezomib-induced apoptosis in MM
cells. (A) SP6000125 (SP), inhibitor of JNK, abrogates PK  bortezomib–induced
release of Smac or cyto-c. MM.1S cells were treated with PK (50 M)  bortezomib
(2 nM) in the presence or absence of SP600125 (SP) and harvested at 24 hours.
Cytosolic proteins were separated by 12.5% SDS-PAGE and analyzed by immuno-
blotting with anti–Cyto-c or anti-Smac (top and middle panels) Abs. As a control for
equal loading of proteins, ﬁlters were also reprobed with antitubulin Ab (bottom
panel). Blots are representative of 3 independent experiments with similar results. (B)
Overexpression of DN-JNK enhances resistance to PK  bortezomib. Cells were
transiently transfected with cDNA expression construct containing GFP with either
DN-JNK (F) or empty vector (f). Following transfections, GFP-positive cells were
selected by ﬂow cytometry; treated with PK (50 M)  bortezomib (2 nM) for 24
hours, 48 hours, or 72 hours; and analyzed for cell viability by MTTassay (P 	 .05, as
determined by one-sided Wilcoxon rank-sum test). Error bars indicate standard error.
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(caspase-8 
 caspase-3) mechanisms; and (5) JNK activation is
required for PK  bortezomib–induced apoptosis in MM cells.
The ﬁnding that PK enhances the anti-MM activity of bortezomib is
consistent with previous studies showing similar effects of PK com-
bined with other anticancer drugs in leukemic cells. For example, PK
sensitizes acute myeloid leukemic (AML) cells to cytarabine.15 PK
blocks p-glycoprotein efﬂux in AML cells, thereby increasing
daunomycin toxicity even in efﬂux competent AML cells.15 A recent
study also showed that PK overcomes multiple drug-resistance mecha-
nisms to increase gentuzumab ozogamicin (GO) sensitivity in AML
cells.54 The mechanism whereby PK sensitizes AML cells to chemo-
therapy activity includes both inhibition of p-glycoprotein–mediated
efﬂux and initiation of mitochondrial apoptosis.54 Our data using MM
cells show that PK enhances bortezomib-triggered cytotoxicity in these
cells via triggering both intrinsic and extrinsic apoptotic pathways. It is
likely that PK increases the intracellular uptake of bortezomib, thereby
enhancing its anti-MM activity; however, whether bortezomib is an
efﬂux pump substrate remains under evaluation. Our data further show
that JNK activation is an obligatory event during PK  bortezomib–
induced apoptosis in MM cells, and these ﬁndings are consistent with a
known role of JNK during stress response in other cell systems.52
Activated JNK translocates to mitochondria and facilitates the release of
cyto-c and Smac; conversely, absence of JNK results in defect in the
mitochondrial death signaling cascades, including failure to release
Smacandcyto-c.Thesedataindeedconﬁrmthefunctionalconsequence
ofJNKactivationduringPKbortezomib–inducedMMcellapoptosis
and establish that mitochondria are affected by proapoptotic signaling
pathways via JNK.
Besides triggering apoptotic signaling pathways, PK  bort-
ezomib also overcomes the major chemoresistance mechanisms in
MM cells. For example, PK  bortezomib overcomes Hsp27-
mediated bortezomib resistance. Additionally, PK  bortezomib
triggers MM cell apoptosis even in the presence of growth and
survival factors for MM cells, such as IL-6 or IGF-1, without
affecting the viability of normals or BMSCs.
Overall, our data exemplify the role of PBR as an endogenous
modulator of mitochondrial apoptosis in MM cells and as a
potential therapeutic target. Importantly, a combination of subtoxic
doses of PBR antagonist PK-11195 and bortezomib triggers
signiﬁcant apoptosis even in MM cells resistant to bortezomib. The
present ﬁndings suggest that combination therapy with PK and
bortezomib may avoid dose-related toxic effects of bortezomib
therapy. Other studies have already shown that PK is nontoxic in
nonobese diabetic–severe combined immunodeﬁciency (NOD-
SCID) mice,54 and is well tolerated in humans.55,56 Together, these
ﬁndings provide a framework for clinical trials of bortezomib with
PK to enhance clinical efﬁcacy, reduce toxicity, and overcome
resistance to conventional and bortezomib therapy in patients with
relapsed refractory MM.
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